Thrombosis and Haemostasis, 0340-6245

Journal

31 - 40 out of 111Page size: 10

Publications

  1. 2013
  2. Published

    Integrin-substrate interactions underlying shear-induced inhibition of the inflammatory response of endothelial cells

    Katie Glen, Stuart Egginton & Gerard Nash, Feb 2013, In: Thrombosis and Haemostasis. 109, 2, p. 298-308 11 p.

    Research output: Contribution to journal › Article › peer-review

  3. Published

    Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey

    Deirdre Lane & Gregory Lip, Feb 2013, In: Thrombosis and Haemostasis. 109, 2, p. 328-36 9 p.

    Research output: Contribution to journal › Article › peer-review

  4. 2012
  5. Published

    Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis

    Gregory Lip, Deirdre Lane, Dec 2012, In: Thrombosis and Haemostasis. 108, 6, p. 1009-22 14 p.

    Research output: Contribution to journal › Article › peer-review

  6. Published

    Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

    Eduard Shantsila & Gregory Lip, 27 Apr 2012, In: Thrombosis and Haemostasis. 108, 1

    Research output: Contribution to journal › Article

  7. Published

    Highlights and hot topics from 2011 in Thrombosis and Haemostasis

    Gregory Lip, 1 Jan 2012, In: Thrombosis and Haemostasis. 107, 1, p. 196-199 4 p.

    Research output: Contribution to journal › Editorial

  8. Published

    Welcome to a new year in Thrombosis and Haemostasis .....

    Gregory Lip, 1 Jan 2012, In: Thrombosis and Haemostasis. 107, 1, p. 1-2 2 p.

    Research output: Contribution to journal › Editorial

  9. 2011
  10. Published

    Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.

    Ami Banerjee, Deirdre Lane & Gregory Lip, 21 Dec 2011, In: Thrombosis and Haemostasis. 107, 3

    Research output: Contribution to journal › Article

  11. Published

    Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis.

    Gregory Lip, Deirdre Lane & Paulus Kirchhof, 30 Nov 2011, In: Thrombosis and Haemostasis. 106, 6, p. 997-1011 15 p.

    Research output: Contribution to journal › Article

  12. Published

    Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference.

    Paulus Kirchhof, Gregory Lip, Deirdre Lane, 30 Nov 2011, In: Thrombosis and Haemostasis. 106, 6, p. 1012-9 8 p.

    Research output: Contribution to journal › Article

  13. Published

    Stroke prevention in non-valvular atrial fibrillation: Can warfarin do better?

    Gregory Lip, 3 Nov 2011, In: Thrombosis and Haemostasis. 106, 5, p. 753-4 2 p.

    Research output: Contribution to journal › Article

Previous 1 2 3 4 5 6 7 8 ...12 Next